These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 15489865

  • 21. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience.
    Martino M, Console G, Dattola A, Callea I, Messina G, Moscato T, Massara E, Irrera G, Fedele R, Gervasi A, Bresolin G, Iacopino P.
    Bone Marrow Transplant; 2009 Aug; 44(3):163-8. PubMed ID: 19182833
    [Abstract] [Full Text] [Related]

  • 22. Granulocyte colony-stimulating factor after autologous CD34+ immunoselected peripheral blood stem cell transplantation.
    Piccirillo N, De Matteis S, Sorà F, d'Onofrio G, Leone G, Sica S.
    Haematologica; 2004 Sep; 89(9):1144-6. PubMed ID: 15377480
    [Abstract] [Full Text] [Related]

  • 23. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders.
    Bittencourt H, Rocha V, Filion A, Ionescu I, Herr AL, Garnier F, Ades L, Esperou H, Devergie A, Ribaud P, Socie G, Gluckman E.
    Bone Marrow Transplant; 2005 Sep; 36(5):431-5. PubMed ID: 15980881
    [Abstract] [Full Text] [Related]

  • 24. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation.
    Atta EH, de Azevedo AM, Maiolino A, Coelho CJ, Sarcinelli SM, de Alvarenga Máximo C, Marra VL.
    Am J Hematol; 2009 Jan; 84(1):21-8. PubMed ID: 19006229
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation.
    Gisselbrecht C, Prentice HG, Bacigalupo A, Biron P, Milpied N, Rubie H, Cunningham D, Legros M, Pico JL, Linch DC.
    Lancet; 1994 Mar 19; 343(8899):696-700. PubMed ID: 7510813
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
    Seymour AM, de Campos E, Thatcher N, De Greve J, Cunningham D, Howell A, Tueni E, Bron DG, Steward WP, Berdel WE.
    Eur J Cancer; 1995 Dec 19; 31A(13-14):2157-63. PubMed ID: 8652235
    [Abstract] [Full Text] [Related]

  • 29. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
    Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, Ruf L, Haas R, Kobbe G.
    Exp Hematol; 2006 Oct 19; 34(10):1296-302. PubMed ID: 16982322
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
    Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, Hoelzer D, Martinez C, Taylor K, Kanz L, To LB, Archimbaud E.
    Ann Hematol; 2003 Nov 19; 82(11):677-83. PubMed ID: 14530872
    [Abstract] [Full Text] [Related]

  • 32. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, Kim JE, Kim S, Lee DH, Lee JS, Park SJ, Park CJ, Huh J, Suh C.
    Transfusion; 2009 Sep 19; 49(9):1890-900. PubMed ID: 19453991
    [Abstract] [Full Text] [Related]

  • 33. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial.
    Faber E, Pytlík R, Slabý J, Zapletalová J, Kozák T, Raida L, Papajík T, Zikesová E, Maresová I, Hamouzová M, Indrák K, Trnený M.
    Eur J Haematol; 2006 Dec 19; 77(6):493-500. PubMed ID: 17042769
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP.
    Biol Blood Marrow Transplant; 2008 Jan 19; 14(1):116-24. PubMed ID: 18158968
    [Abstract] [Full Text] [Related]

  • 38. Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilization.
    Thompson JM, Carlton P, Akard LP, Dugan MJ, Jansen J.
    Transfusion; 2009 Mar 19; 49(3):548-54. PubMed ID: 19040494
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.